Related references
Note: Only part of the references are listed.Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis
Maria P. Sormani et al.
ANNALS OF NEUROLOGY (2021)
Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore
Barnaby Edward Young et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Clinical Characteristics of Coronavirus Disease 2019 in China
W. Guan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
SARS-CoV-2 and Multiple Sclerosis: Not All Immune Depleting DMTs are Equal or Bad
Sandra Amor et al.
ANNALS OF NEUROLOGY (2020)
Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China
Chuan Qin et al.
CLINICAL INFECTIOUS DISEASES (2020)
Predictors of hospitalization in a Canadian MS population: A matched cohort study
Lina H. Al-Sakran et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Sex-Specific SARS-CoV-2 Mortality: Among Hormone-Modulated ACE2 Expression, Risk of Venous Thromboembolism and Hypovitaminosis D
Sandro La Vignera et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
COVID-19 illness in native and immunosuppressed states: A clinical?therapeutic staging proposal
Hasan K. Siddiqi et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2020)
Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic
Lorenzo D'Antiga
LIVER TRANSPLANTATION (2020)
被撤回的出版物: Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 (Publication with Expression of Concern. See vol. 382, pg. 2464, 2020) (Retracted article. See vol. 382, pg. 2582, 2020)
Mandeep R. Mehra et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
COVID-19 and MS disease-modifying therapies
Joseph R. Berger et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)
Gender Differences in Patients With COVID-19: Focus on Severity and Mortality
Jian-Min Jin et al.
FRONTIERS IN PUBLIC HEALTH (2020)
Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis
Celine Louapre et al.
JAMA NEUROLOGY (2020)
COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?
Giovanni Novi et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
COVID-19 in multiple sclerosis: The Dutch experience
Floor C. Loonstra et al.
MULTIPLE SCLEROSIS JOURNAL (2020)
EMCAM (Multiple Sclerosis Autonomous Community of Madrid) document for the management of patients with multiple sclerosis during the SARS-CoV-2 pandemic
Lucienne Costa-Frossard et al.
REVISTA DE NEUROLOGIA (2020)
The prevalence of MS in the United States A population-based estimate using health claims data
Mitchell T. Wallin et al.
NEUROLOGY (2019)
All-cause hospitalizations in multiple sclerosis patients
Carolina Maia et al.
REVISTA DE NEUROLOGIA (2019)
Increase in the prevalence of multiple sclerosis over a 17-year period in Osona, Catalonia, Spain
S. Otero-Romero et al.
MULTIPLE SCLEROSIS JOURNAL (2013)
A solution to separation in binary response models
C Zorn
POLITICAL ANALYSIS (2005)
Share Paper
